Insys Therapeutics (NASDAQ: INSY) reported Q4 EPS of $0.36, $0.07 better than the analyst estimate of $0.29. Revenue for the quarter came in at $91.1 million versus the consensus estimate of $91.04 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.